382 related articles for article (PubMed ID: 33921638)
21. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.
Petroni M; Sardina F; Infante P; Bartolazzi A; Locatelli E; Fabretti F; Di Giulio S; Capalbo C; Cardinali B; Coppa A; Tessitore A; Colicchia V; Sahùn Roncero M; Belardinilli F; Di Marcotullio L; Soddu S; Comes Franchini M; Petricci E; Gulino A; Giannini G
Cell Death Dis; 2018 Aug; 9(9):895. PubMed ID: 30166519
[TBL] [Abstract][Full Text] [Related]
22. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
23. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
24. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
[TBL] [Abstract][Full Text] [Related]
25. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
26. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.
Lee KJ; Wright G; Bryant H; Wiggins LA; Schuler M; Gassman NR
Cancer Drug Resist; 2020; 3(4):980-991. PubMed ID: 35582228
[No Abstract] [Full Text] [Related]
27. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.
Wayne J; Brooks T; Massey AJ
Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224
[TBL] [Abstract][Full Text] [Related]
28. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
29. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
30. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms.
King C; Diaz HB; McNeely S; Barnard D; Dempsey J; Blosser W; Beckmann R; Barda D; Marshall MS
Mol Cancer Ther; 2015 Sep; 14(9):2004-13. PubMed ID: 26141948
[TBL] [Abstract][Full Text] [Related]
31. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
32. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death.
van Harten AM; Buijze M; van der Mast R; Rooimans MA; Martens-de Kemp SR; Bachas C; Brink A; Stigter-van Walsum M; Wolthuis RMF; Brakenhoff RH
Oncogenesis; 2019 Jun; 8(7):38. PubMed ID: 31209198
[TBL] [Abstract][Full Text] [Related]
33. Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer.
Deneka AY; Einarson MB; Bennett J; Nikonova AS; Elmekawy M; Zhou Y; Lee JW; Burtness BA; Golemis EA
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012873
[TBL] [Abstract][Full Text] [Related]
34. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
35. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
[TBL] [Abstract][Full Text] [Related]
36. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
37. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.
Ronco C; Martin AR; Demange L; Benhida R
Medchemcomm; 2017 Feb; 8(2):295-319. PubMed ID: 30108746
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors.
Gu P; Xue L; Zhao C; Li W; Jiang Z; Liu A; Li T; Liu L; Decker M; Cheng X; Yang W; Tang R
Front Oncol; 2022; 12():885186. PubMed ID: 35646698
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.
Wang D; Fu L; Sun H; Guo L; DuBois RN
Gastroenterology; 2015 Dec; 149(7):1884-1895.e4. PubMed ID: 26261008
[TBL] [Abstract][Full Text] [Related]
40. Extensive RPA2 hyperphosphorylation promotes apoptosis in response to DNA replication stress in CHK1 inhibited cells.
Zuazua-Villar P; Ganesh A; Phear G; Gagou ME; Meuth M
Nucleic Acids Res; 2015 Nov; 43(20):9776-87. PubMed ID: 26271993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
